Literature DB >> 10986395

A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping.

F G Leppers-van de Straat1, W L van der Pol, M D Jansen, N Sugita, H Yoshie, T Kobayashi, J G van de Winkel.   

Abstract

Leukocyte IgG receptors (Fc gamma R) are important immune-response modulating molecules. Fc gamma RIIIa is expressed on macrophages, NK-cells and gamma delta-T cells and exhibits a genetically determined, functional polymorphism at nucleotide 559. This allelic difference predicts either a phenylalanine (F158) or valine (V158) at amino acid 158 in the membrane-proximal extracellular domain, and has been shown to be associated with autoimmune and infectious diseases. Published methods to determine Fc gamma RIIIa genotypes are cumbersome. Therefore, we developed a novel, rapid and reliable PCR-based method to determine Fc gamma RIIIa genotypes. Comparison of genotyping results with direct Fc gamma RIIIa sequencing of 60 blood donors showed 100% accuracy of this new method. Since genotype frequencies of Fc gamma R polymorphisms depend strongly on race and ethnicity, we compared Fc gamma RIIIa genotype frequencies of 176 Caucasian Dutch and 104 Japanese blood donors. Interestingly, these frequencies were not significantly different (P>0.1), in contrast to the Fc gamma RIIa and Fc gamma RIIIb genotype frequencies (P<0.001).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10986395     DOI: 10.1016/s0022-1759(00)00240-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  19 in total

1.  Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo.

Authors:  Anne Baerenwaldt; Anja Lux; Heike Danzer; Bernd M Spriewald; Evelyn Ullrich; Gordon Heidkamp; Diana Dudziak; Falk Nimmerjahn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

2.  Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations.

Authors:  Oivind Torkildsen; Egil Utsi; Svein Ivar Mellgren; Hanne F Harbo; Christian A Vedeler; Kjell-Morten Myhr
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

3.  Distribution of the FcgammaRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore.

Authors:  K T Chong; W F Ho; S H Koo; Peter Thompson; Edmund J D Lee
Journal:  Br J Clin Pharmacol       Date:  2006-09-19       Impact factor: 4.335

4.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

5.  Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

Authors:  Julie A Bowles; Siao-Yi Wang; Brian K Link; Barrett Allan; Gregory Beuerlein; Mary-Ann Campbell; David Marquis; Brian Ondek; James E Wooldridge; Brian J Smith; James B Breitmeyer; George J Weiner
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

6.  Evidence for non-random distribution of Fcgamma receptor genotype combinations.

Authors:  W-Ludo van der Pol; Marc D Jansen; Wim J Sluiter; Bart van de Sluis; Fredriek G J Leppers-van de Straat; Tetsuo Kobayashi; Rudi G J Westendorp; Tom W J Huizinga; Jan G J van de Winkel
Journal:  Immunogenetics       Date:  2003-06-26       Impact factor: 2.846

7.  Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms.

Authors:  K Manger; R Repp; M Jansen; M Geisselbrecht; R Wassmuth; N A C Westerdaal; A Pfahlberg; B Manger; J R Kalden; J G J van de Winkel
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

8.  Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Authors:  Liat Binyamin; R Katherine Alpaugh; Tracey L Hughes; Charles T Lutz; Kerry S Campbell; Louis M Weiner
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

9.  Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.

Authors:  Minkyu Jung; Ja Seung Koo; Young Wha Moon; Byeong-Woo Park; Seung Il Kim; Seho Park; Soo Hyun Lee; Soojung Hong; Sun Young Rha; Hyun Cheol Chung; Joo Hang Kim; Joohyuk Sohn
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

10.  Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.

Authors:  Rosa Calemma; Alessandro Ottaiano; Anna Maria Trotta; Guglielmo Nasti; Carmela Romano; Maria Napolitano; Domenico Galati; Pasquale Borrelli; Serena Zanotta; Antonino Cassata; Giuseppe Castello; Vincenzo Rosario Iaffaioli; Stefania Scala
Journal:  J Transl Med       Date:  2012-11-21       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.